Qureight, an AI-driven company, has achieved a significant breakthrough in lung disease research by replacing traditional placebo groups with synthetic control arms. This innovative approach was utilized in a clinical trial for idiopathic pulmonary fibrosis (IPF), assessing a new inhaled therapy.
Qureight's technology uses a deep-learning platform and historical patient data to create a comparable control group. This method is particularly beneficial for rare diseases like IPF, where patient recruitment is challenging. By pairing treated patients with synthetic groups, Qureight aims to speed up trials and reduce the need for placebos, improving efficiency and aligning with ethical research practices.
At the American Thoracic Society 2025 International Conference, the results of clinical trials for a new inhaled therapy for idiopathic pulmonary fibrosis were presented. Data from the first phase of trials showed an acceptable safety profile, which lays the foundation for the transition to the second phase of clinical trials.